Literature DB >> 7689059

Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin.

T Hoof1, A Demmer, U Christians, B Tümmler.   

Abstract

The ability of cyclosporin A, FK506, and rapamycin to overcome multidrug resistance was investigated in Chinese hamster ovary cells in vitro by growth inhibition experiments. 1-30 microM of immunosuppressant sensitized drug-resistant cells and their drug-sensitive parents in a dose-dependent manner to adriamycin (2-2000-fold), colchicine (2-260-fold), and vinblastine (2-120-fold). The multidrug resistance-reversing activity increased in the order rapamycin < FK506 < cyclosporin A, irrespective of whether the resistant cells overexpressed hamster or human P-glycoprotein. The interaction of the three macrolides with P-glycoprotein was characterized by their ability to competitively inhibit the photoaffinity labelling of plasma membranes of resistant CHRB30 cells by iodomycin. The three immunosuppressants bound with high affinity to P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689059     DOI: 10.1016/0922-4106(93)90009-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  RAD001 can reverse drug resistance of SGC7901/DDP cells.

Authors:  Liu Ying; Zhu Zu-An; Liu Qing-Hua; Kong Qing-Yan; Liu Lei; Cui Tao; Wu Yong-Ping
Journal:  Tumour Biol       Date:  2014-06-12

2.  Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

Authors:  Craig C Hofmeister; Xiaoxia Yang; Flavia Pichiorri; Ping Chen; Darlene M Rozewski; Amy J Johnson; Seungsoo Lee; Zhongfa Liu; Celia L Garr; Erinn M Hade; Jia Ji; Larry J Schaaf; Don M Benson; Eric H Kraut; William J Hicks; Kenneth K Chan; Ching-Shih Chen; Sherif S Farag; Michael R Grever; John C Byrd; Mitch A Phelps
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

3.  Modulation of Multidrug Resistance in Cancer by Immunosuppresive Agents. Preclinical Studies.

Authors:  Adorján Aszalos
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

4.  In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.

Authors:  A Crowe; M Lemaire
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

5.  Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein.

Authors:  K Tanaka; M Hirai; Y Tanigawara; M Yasuhara; R Hori; K Ueda; K Inui
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 6.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Authors:  Chunjing Wu; Medhi Wangpaichitr; Lynn Feun; Marcus Tien Kuo; Carlos Robles; Theodore Lampidis; Niramol Savaraj
Journal:  Mol Cancer       Date:  2005-07-20       Impact factor: 27.401

8.  Hypoxia as a target for drug combination therapy of liver cancer.

Authors:  Cressida Bowyer; Andrew L Lewis; Andrew W Lloyd; Gary J Phillips; Wendy M Macfarlane
Journal:  Anticancer Drugs       Date:  2017-08       Impact factor: 2.248

9.  Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR.

Authors:  Zhibo Hou; Yi Wang; Ning Xia; Tangfeng Lv; Xiaoqin Yuan; Yong Song
Journal:  Cancer Sci       Date:  2020-11-28       Impact factor: 6.518

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.